Status:
UNKNOWN
The Dose of Radioactive Iodine Needed to Ablate the Thyroid Remnant Left Behind After Thyroidectomy
Lead Sponsor:
University of Helsinki
Collaborating Sponsors:
Helsinki University Central Hospital
Conditions:
Thyroid Neoplasms
Eligibility:
All Genders
18+ years
Phase:
PHASE3
Brief Summary
The thyroid cells take up iodine, and radioactive iodine is commonly used to irradiate residual thyroid tissue and thyroid cancer following surgical removal of the thyroid gland (thyroidectomy). A who...
Detailed Description
The study participants are randomly allocated to receive either a 1110 MBq or a 3700 MBq dose of radioiodine (131I) approximately 5 weeks after thyroidectomy. Thyroxin substitution is initiated only a...
Eligibility Criteria
Inclusion
- Inclusion criteria:
- Total or near total thyroidectomy performed for papillary or follicular thyroid cancer
- R0-1 resection, no macroscopic cancer left behind at surgery
- Physically and emotionally able to undergo radioiodine treatment
- A written informed consent
- Exclusion criteria:
- Pregnancy
- Physical or psychiatric illness that may deteriorate during the isolation period required by radioiodine therapy
Exclusion
Key Trial Info
Start Date :
January 1 2000
Trial Type :
INTERVENTIONAL
Allocation :
ACTUAL
End Date :
September 1 2020
Estimated Enrollment :
160 Patients enrolled
Trial Details
Trial ID
NCT00115895
Start Date
January 1 2000
End Date
September 1 2020
Last Update
March 2 2018
Active Locations (1)
Enter a location and click search to find clinical trials sorted by distance.
1
Helsinki University Central Hospital, Department of Oncology
Helsinki, Finland, FIN-00029HUS